What is the role of combination liposomal cytarabine and daunorubicin (Vyxeos) in the treatment of acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Older patients with AML with myelodysplasia-related changes are eligible for liposomal cytarabine and daunorubicin (Vyxeos). In the registration study, which also included patients with therapy-related AML, 309 patients aged 60-75 years received the liposomal combination product or cytarabine and daunorubicin given separately, in the 3+7 regimen. The CR or CRi rate was 47.7% for the combination, compared with 33.3% for 3+7. OS at 12 and 24 months for the fixed-dose combination was 41.5% and 31.1%, respectively,  compared with OS of 27.6% and 12.3% with 3+7. [72]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!